Skip to main content
OpenTrials
Completed

NCT Number: NCT03378531

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency

The purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Complete treatment in Study CAEB1102-101A without experiencing any clinically significant adverse event or other unmanageable drug toxicity that would preclude continued dosing
  • Confirmation by the Investigator and the Sponsor determine that it is acceptable for the patient to continue dosing with AEB1102
  • If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
  • If sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
  • Patient or legal guardian is able and willing to provide written informed consent and where required assent, and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification), prior to any screening procedures

Exclusion criteria

  • Clinically significant concurrent disease, serious intercurrent illness, or other extenuating circumstances

Treatment and study plan

AEB1102

Drug

modified human arginase I

Other names: Co-ArgI-PEG, Pegzilarginase

Primary outcomes

  1. Number of Participants With Treatment-related Adverse Events

    Time frame: From start of study up to 262 weeks

  2. Number of Participants With Anti-pegzilarginase and Anti-PEG Antibodies

    Time frame: From start of study up to 262 weeks

Secondary outcomes

  1. Plasma Arginine Levels

    Time frame: From start of study up to 240 weeks

    Change in plasma arginine concentrations from study Baseline

  2. Plasma GC Levels (Argininic Acid)

    Time frame: From start of study up to 240 weeks

    Change in plasma argininic acid concentrations from study Baseline

  3. Plasma GC Levels (Guanidinoacetic Acid)

    Time frame: From start of study up to 240 weeks

    Change in plasma guanidinoacetic acid concentrations from study Baseline

  4. Plasma GC Levels (α-keto-δ-guanidinovaleric Acid)

    Time frame: From start of study up to 240 weeks

    Change in plasma α-keto-δ-guanidinovaleric acid concentrations from study Baseline

  5. Plasma GC Levels (α-N-acetylarginine)

    Time frame: From start of study up to 240 weeks

    Change in plasma α-N-acetylarginine concentrations from study Baseline

  6. Six-Minute Walk Test (6MWT)

    Time frame: From start of study up to 262 weeks

    Change in 6MWT distance from study Baseline

  7. Gross Motor Function Measure (GMFM) Part D

    Time frame: From start of study up to 262 weeks

    Change from study Baseline. The GMFM-D evaluates the patient's ability to stand via assessment of 13 activities, each of which is scored on a scale of 0 to 3, with a scale range of 0-39 points. An increase in GMFM-D score indicates improvement in standing.

  8. Gross Motor Function Measure (GMFM) Part E

    Time frame: From start of study up to 262 weeks

    Change from study Baseline. The GMFM-E evaluates a subject's ability to walk, run, and jump via assessment of 24 activities, each of which is scored on a scale of 0 to 3, , with a scale range of 0-72. A higher GMFM-E score indicates greater ability, with increasing scores indicating improvement in walking, running, and jumping.

  9. Modified Ashworth Scale (MAS)

    Time frame: From start of study up to 262 weeks

    Spasticity improvement for lower body muscle groups based on MAS from study Baseline. The MAS is used to measure the resistance to passive movement about a joint due to spasticity using a 6-point scoring scale with possible values of 0, 1, 1+ (scored as 1.5), 2, 3, and 4, where 0 is no increase in muscle tone (no spasticity) and 4 is affected part(s) rigid in flexion or extension (total rigidity). Thus, a decrease in MAS score indicates improvement in spasticity.

  10. Berg Balance Scale (BBS)

    Time frame: From start of study up to 262 weeks

    Change from study Baseline. The BBS, a measure of balance, utilizes a 5-point scoring scale of 0 (indicating the lowest level of function) to 4 (indicating the highest level of function) for 14 tasks, giving a scale range of 0-56, with a higher score representing better balance.

  11. Purdue Pegboard Test (Dominant Hand)

    Time frame: From start of study up to 262 weeks

    Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average.

  12. Purdue Pegboard Test (Non-dominant Hand)

    Time frame: From start of study up to 262 weeks

    Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average.

  13. Number of Participants With Hyperammonemic Episodes

    Time frame: From study start up to 262 weeks

    Hyperammonemic episodes" are defined as either an AE for which an Investigator observed symptoms considered to be consistent with a "hyperammonemic episode", or an AE in a patient meeting all 3 of the following criteria: 1. Confirmed ammonia level ≥100 μM, 2. One or more symptoms related to hyperammonemia, 3. Requiring hospitalization or emergency room management.

  14. Number of Participants With Seizures

    Time frame: From study start up to 262 weeks

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Immedica Pharma AB

Industry

Collaborators

  • Aeglea Biotherapeutics

Registry information

Official study title

An Open-label, Multicentre Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of AEB1102 in Patients With Arginase 1 Deficiency

Important dates

Study start
2017
Primary completion
2022
Study completion
2022
First posted
Dec 20, 2017
Registry last updated
Sep 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.